AbbVie
AbbVie is an American biopharmaceutical company created in 2013 following its corporate separation from Abbott Laboratories. The company researches, manufactures, and markets biological and small-molecule pharmaceuticals in therapeutic areas including immunology, oncology, neuroscience, eye care, and medical aesthetics. Key commercial products within its portfolio include Humira, Skyrizi, Rinvoq, Imbruvica, and Botox treatments. Revenue drivers consist primarily of wholesale sales of patented biopharmaceutical treatments to healthcare distributors, pharmacy networks, and medical institutions globally. AbbVie ranks among the world's highest-revenue biopharmaceutical firms with extensive commercial operations across international healthcare markets. The enterprise is headquartered in North Chicago, Illinois, and traded on the New York Stock Exchange under the ticker symbol ABBV.
138 of the funds FundTelligence covers report a position in AbbVie.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 138
- Exposure themes
- Multiple, Reproductive health, Treatment, Women's Health
Funds holding AbbVie
- Fidelity Global Healthcare Fund — Fidelity · 8.1 % (largest positions only, October 2026)
- Handelsbanken Helse Tema — Handelsbanken · 7.37 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 7.28 % (full portfolio disclosed, October 2026)
- JPM Global Healthcare Fund — JPM · 6.94 % (full portfolio disclosed, June 2026)
- BGF World Healthscience Fund — BlackRock · 6.53 % (largest positions only, October 2026)
- HealthInvest Sustainable Healthcare — HealthInvest · 6.2 % (partially disclosed portfolio, September 2026)
- DNB Health Care — DNB · 5.75 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 5.73 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 138 funds holding it.